A Phase 1 interventional study of Filgotinib in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-15.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1, and was the 10th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
12 studies in Arthritis, Rheumatoid by Gilead Sciences: none open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 1, and was the 8th registered.
Gilead Sciences’s Arthritis, Rheumatoid studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 12 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.
Key Inclusion Criteria:
Individuals with hepatic impairment will be categorized by the -Turcotte (CPT) classification system indicating hepatic impairment as follows:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
Drug: Filgotinib
Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
Drug: Filgotinib
Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
Drug: Filgotinib
100 mg tablet administered orally
Also known as: GS-6034, GLPG0634
Pharmacokinetic (PK) Parameter: AUClast of Filgotinib
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
PK Parameter: AUClast of GS-829845
AUClast is defined as the concentration of drug from time zero to the last observable concentration. GS-829845 is the primary metabolite of filgotinib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
PK Parameter: AUCinf of Filgotinib
AUCinf is defined as the concentration of drug extrapolated to infinite time.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
PK Parameter: AUCinf of GS-829845
AUCinf is defined as the concentration of drug extrapolated to infinite time. GS-829845 is the primary metabolite of filgotinib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
PK Parameter: Cmax of Filgotinib
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
PK Parameter: Cmax of GS-829845
Cmax is defined as the maximum observed concentration of drug. GS-829845 is the primary metabolite of filgotinib.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
Time frame: Day 1 up to Day 31
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Day 1 up to Day 31
Participants were enrolled at study sites in Germany, New Zealand, and United States. The first participant was screened on 03 April 2018. The last study visit occurred on 09 August 2018.
| Milestone | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| Pharmacokinetic (PK) Parameter: AUClast of Filgotinib | 2389.3 ± 530.85 | 1981.9 ± 995.78 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration. GS-829845 is the primary metabolite of filgotinib.
| h*ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| PK Parameter: AUClast of GS-829845 | 32466.8 ± 10898.85 | 31412.6 ± 13758.34 |
AUCinf is defined as the concentration of drug extrapolated to infinite time.
| h*ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| PK Parameter: AUCinf of Filgotinib | 2417.0 ± 533.74 | 1995.9 ± 997.88 |
AUCinf is defined as the concentration of drug extrapolated to infinite time. GS-829845 is the primary metabolite of filgotinib.
| h*ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| PK Parameter: AUCinf of GS-829845 | 33296.5 ± 11568.33 | 32060.0 ± 14329.57 |
Cmax is defined as the maximum observed concentration of drug.
| ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| PK Parameter: Cmax of Filgotinib | 722.6 ± 293.24 | 802.2 ± 485.98 |
Cmax is defined as the maximum observed concentration of drug. GS-829845 is the primary metabolite of filgotinib.
| ng/mL | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| PK Parameter: Cmax of GS-829845 | 972.5 ± 256.09 | 1122.6 ± 447.45 |
| percentage of participants | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | 30.0 | 10.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| Any Laboratory Abnormality | 90.0 | 70.0 |
| Grade 3 or 4 Laboratory Abnormalities | 60.0 | 0.0 |
Collected over Day 1 up to Day 31. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moderate Hepatic Impairment | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Healthy Control | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Moderate Hepatic Impairment | Healthy Control |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/10 |
| Chest discomfortGeneral disorders | 1/10 | 0/10 |
| RhinitisInfections and infestations | 0/10 | 1/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 |
| Rash papularSkin and subcutaneous tissue disorders | 1/10 | 0/10 |
The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Moderate Hepatic Impairment | Healthy Control | Total |
|---|---|---|---|
| Mean | 61 ± 6.9 | 62 ± 5.3 | 61 ± 6.1 |
| Sex: Female, Male(Participants) | Moderate Hepatic Impairment | Healthy Control | Total |
|---|---|---|---|
| Female | 7 | 7 | 14 |
| Male | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Moderate Hepatic Impairment | Healthy Control | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 5 | 5 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Moderate Hepatic Impairment | Healthy Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 10 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Moderate Hepatic Impairment | Healthy Control | Total |
|---|---|---|---|
| New Zealand | 2 | 2 | 4 |
| United States | 6 | 6 | 12 |
| Germany | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Aug 2018, 4 months.
Results were first posted in Jan 2021, 2 years 5 months after primary completion.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 4 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634